EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/fN01V1PBfY https://t.co/UgULLHunky